High-dose chemotherapy with autologous stem-cell rescue in patients with recurrent and high-risk pediatric brain tumors

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
M L GrahamHenry S Friedman

Abstract

We treated 49 patients with recurrent or poor-prognosis CNS malignancies with high-dose chemotherapy regimens followed by autologous marrow rescue with or without peripheral-blood stem-cell augmentation to determine the toxicity of and event-free survival after these regimens. Nineteen patients had medulloblastomas, 12 had glial tumors, seven had pineoblastomas, five had ependymomas, three had primitive neuroectodermal tumors, two had germ cell tumors, and one had fibrosarcoma. Thirty-seven received chemotherapy with cyclophosphamide 1.5 g/m2 daily x 4 and melphalan 25 to 60 mg/m2 daily x 3. Nine received busulfan 37.5 mg/m2 every 6 hours x 16 and melphalan 180 mg/m2 (n = 7) or 140 mg/m2 (n = 2). Three received carboplatin 700 mg/m2/d on days -7, -5, and -3 and etoposide 500 mg/m2/d on days -6, -4, and -2. All patients received standard supportive care. Eighteen of 49 patients survive event-free 22+ to 55+ months (median, 33+) after transplantation, including nine of 16 treated before recurrence and nine of 33 treated after recurrence. There was one transplant-related death from pulmonary aspergillosis. Of five patients assessable for disease response, one had a partial remission (2 months), one has had stable disease (55+ mont...Continue Reading

Citations

Feb 9, 2006·Pediatric Neurosurgery·Masamitsu AbeJunichi Imamura
Jun 9, 2006·Expert Review of Anticancer Therapy·Maura Massimino, Veronica Biassoni
Apr 1, 2014·Journal of Investigative Medicine High Impact Case Reports·Abhimanyu GhoseSadia Benzaquen
Oct 21, 2016·Pediatric Blood & Cancer·Ashley S PlantLindsay Frazier
Feb 16, 2019·Pediatric Blood & Cancer·Mohammad H Abu ArjaMohamed S AbdelBaki
May 31, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sridharan GururanganPaul L Martin
Sep 7, 2004·Annals of Neurology·Wojciech RzeskiChrysanthy Ikonomidou
Apr 17, 2008·Journal of Neuro-oncology·Stephen W GilheeneyMark W Kieran
May 22, 2009·Child's Nervous System : ChNS : Official Journal of the International Society for Pediatric Neurosurgery·Kyu-Won ShimJoong-Uhn Choi
Mar 21, 2009·Journal of Neuroscience Research·Seung U Kim, Jean de Vellis
Mar 20, 1999·Current Opinion in Pediatrics·J B Rubin, M W Kieran
Apr 9, 2002·Current Neurology and Neuroscience Reports·Dale F KraemerEdward A Neuwelt
May 23, 2006·Pediatric Neurosurgery·Takashi TamiyaIsao Date
Aug 5, 2003·Paediatric Drugs·Jacques GrillKalifa Chantal
Jan 29, 2002·Medical and Pediatric Oncology·Bilgehan YalçinCanan Akyüz
Apr 7, 2010·Expert Review of Neurotherapeutics·Dattatraya Muzumdar, Enrique C G Ventureyra
Oct 27, 2015·Pediatric Blood & Cancer·Rajkumar VenkatramaniMurali Chintagumpala
Jun 27, 2019·Current Treatment Options in Oncology·Nazanin Majd, Marta Penas-Prado
Feb 12, 1998·Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]·R D Kortmann
Oct 2, 2007·Journal of Neuro-oncology·Daniel Ka Leung CheukGodfrey Chi Fung Chan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aspergillosis

Aspergillosis is the name given to a wide variety of diseases caused by infection by fungi of the genus Aspergillus. Aspergillosis occurs in chronic or acute forms which are clinically very distinct. Most cases of acute aspergillosis occur in patients with severely compromised immune systems. Chronic colonization or infection can cause complications in people with underlying respiratory illnesses. Discover the latest research on aspergillosis here.

Aspergillosis (ASM)

Aspergillosis is the name given to a wide variety of diseases caused by infection by fungi of the genus Aspergillus. Aspergillosis occurs in chronic or acute forms which are clinically very distinct. Most cases of acute aspergillosis occur in patients with severely compromised immune systems. Chronic colonization or infection can cause complications in people with underlying respiratory illnesses. Discover the latest research on aspergillosis here.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Morris KletzelSusan L Cohn
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Shakeel ModakJ L Finlay
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Philip J BiermanJ O Armitage
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
M LegrosR Plagne
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
W I BensingerC D Buckner
© 2021 Meta ULC. All rights reserved